← Back
Data updated: Jun 28, 2026
EMMAUS MEDCL
Pharma Pharmaceuticals
EMMAUS MEDCL is a pharmaceutical company with 2 FDA-approved products.
2004
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
EMMAUS MEDCL's Key Drugs
EMMAUS MEDCL's core commercial portfolio centers on ENDARI — its most strategically important drugs approved in the last 15 years.
EMMAUS MEDCL's Recent FDA Approvals
New NDA/BLA approvals for EMMAUS MEDCL over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
EMMAUS MEDCL's Therapeutic Areas
Disease areas where EMMAUS MEDCL has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
EMMAUS MEDCL Pipeline Snapshot
Active clinical trials for EMMAUS MEDCL across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ENDARI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2004-06-10
- Latest
- 2025-06-18
- Applications
- 2